Pilot Study of Effects of Bazedoxifene plus Conjugated Estrogen on Imaging and Blood Biomarkers In Women with Menopausal Symptoms at Increased Risk for Breast Cancer
A Phase III Study That Will Evaluate The Safety And Efficacy Of The Study Drug A Reversible Dual Inhibitor That Selectively Targets Phosphoinositide 3-Kinase PI3K And Mammalian Target Of Rapamycin Mtor In Patients With HR+/HER2- Locally Advanced Or Metastatic Breast Cancer Who Have Progressed On Or After Treatment With A CDK 4/6 Inhibitor
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Alpelisib BYL719 in Combination with Nab-Paclitaxel in Patients with Advanced Triple Negative Breast Cancer with Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha PIK3CA Mutation or Phosphatase and Tensin Homolog Protein PTEN Loss Without PIK3CA Mutation
Elacestrant Monotherapy for the Treatment of Postmenopausal Women with ER+/HER2- Advanced Breast Cancer Following Cdk4/6 Inhibitor Therapy: A Phase III Randomized, Open-Label, Multicenter Trial EMERALD
A Phase III Open-label, Randomised Study of Datopotamab Deruxtecan Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy TROPION-Breast03
Palbociclib After CDK and Endocrine Therapy PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2-Metastatic Breast Cancer
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
Randomized IIB Study of the Effect of Bazedoxifene plus Conjugated Estrogens on Breast Imaging and Tissue Biomarkers in Peri or Post-Menopausal Women at Increased Risk for Development of Breast Cancer